Antiviral drugs can be less costly than flu shots

	Tweet

An ounce of prevention is worth a pound of cure, the saying goes—but it may not always hold true when it comes to the flu.

Influenza vaccination for healthy working adults is “reasonable” from public health standpoint, but it is not necessarily a cost-saving measure, according to researchers. In general, antiviral treatment of the flu with amantadine (Symmetrel) is more cost-effective than preventive flu vaccination.

Drs. Michael B. Rothberg and David N. Rose, of Tufts University School of Medicine in Boston, compared outcomes of four strategies: annual flu vaccination, amantadine given when a case of flu is suspected, rapid testing for influenza infection followed by treatment with oseltamivir (Tamiflu) if results are positive, or no intervention.

They used reports from the World Health Organization and Centers for Disease Control and Prevention regarding week-by-week incidence of influenza-like illness for 1993 through 2002. They assumed that workers miss an average of 1.9 days for an influenza-like illness and that 40 percent of patients visit a physician within 48 hours of symptom onset.

Overall, amantadine was the least expensive strategy at $234 per person per year, whereas vaccination costs averaged out to $239 per person, according to the team’s report in the American Journal of Medicine.

For every influenza season except 1997-1998, however, annual vaccination was the most effective strategy in keeping workers on the job and out of the hospital, and in four seasons it was the least expensive.

“If vaccination cost was less than $16 or time lost from work exceeded 2.4 days per episode of influenza, then vaccination was cost saving compared with all other strategies,” the investigators add.

No intervention was the least effective and most expensive option.

“Encouraging employees to seek prompt medical attention for fever and cough during the influenza season appears to save money, even for patients who have already been vaccinated, especially in years when the vaccine is not well matched to circulating strains of influenza,” Rothberg and Rose conclude.

SOURCE: American Journal of Medicine, January 2005.

------------------------------
Tamiflu is an antiviral agent used to treat the flu (Influenza A and B) in patients who have had symptoms for no more than 2 days.

TAMIFLU (TAM-ih-flew) is a medicine to treat flu (infection caused by influenza virus). It belongs to a group of medicines called neuraminidase inhibitors. These medications attack the influenza virus and prevent it from spreading inside your body. TAMIFLU treats flu at its source by attacking the virus that causes the flu, rather than simply masking symptoms. Each TAMIFLU capsule (grey/light yellow) contains 75 mg of active drug and should be taken by mouth.

RELATED STORIES:
Pfizer Endometriosis Pain Drug Gets OK’d   GSK tests intravenous flu drug vs Roche’s Tamiflu   Antidepressants give drugmakers the blues   Short antibiotic course effective in COPD flare-ups   Novartis wins $220 mln U.S. flu vaccine contract   Introgen files for FDA approval of cancer drug   FDA approves Azilect for the treatment of Parkinson’s   ADHD drug use in US rose among ages 20-44: study   Separate profit from research, agency advises   ACE inhibitors helpful in heart and kidney disease   Onyx Shares Fall on Cancer Drug Filing   Chinese scientists develop bird flu vaccine - media

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]